Functional consequence of MDR1 expression on imatinib intracellular concentrations [1]

Blood

Volumn 102, Issue 3, 2003, Pages 1142-

  Widmer, Nicolas ^b   Colombo, Sara ^b   Buclin, Thierry ^b   Decosterd, Laurent A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; IMATINIB;

ANIMAL CELL; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); DRUG ACCUMULATION; DRUG DIFFUSION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TRANSPORT; GENE; GENE EXPRESSION; LETTER; MDR1 GENE; NONHUMAN; PRIORITY JOURNAL;

EID: 0043245793     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0993     Document Type: Letter

References (9)

1. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368-2373.
2. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
3. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.
4. Nimmanapalli R, Bhalla K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol. 2002;14:616-620.
5. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et Biophysica Acta. 2002;1587:318-325.
6. Zhang Y, Bachmeier C, Miller DW. In vitro and in vivo models for assessing drug efflux transporter activity. Adv Drug Deliv Rev. 2003;55:31-51.
7. Schinkel AH, Wagenaar E, Vandeemter L, Mol CAAM, Borst P. Absence of the Mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine-A. J Clin Invest. 1995;96:1698-1705.
8. Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res. 1990;14:11-21.
9. Stavrovskaya A, Turkina A, Sedyakhina N, et al. Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia. Leuk Lymph. 1998;28:469-482.